You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ocrelizumab

Showing 1 - 25 of 116
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Sclerosis Trial (Ocrelizumab Injection [Ocrevus])

Not yet recruiting
  • Multiple Sclerosis
  • Ocrelizumab Injection [Ocrevus]
  • (no location specified)
Aug 22, 2023

Ocrelizumab on Cortical Lesion Accumulation in PPMS

Not yet recruiting
  • Primary Progressive Multiple Sclerosis
  • Ocrelizumab
  • (no location specified)
Aug 2, 2023

Ocrelizumab Effects on the Metabolome in MS

Active, not recruiting
  • Multiple Sclerosis
  • Ocrelizumab
  • Baltimore, Maryland
    Johns Hopkins University
Jan 30, 2023

Ocrelizumab on Choroid Plexus Changes in Patients With PPMS

Not yet recruiting
  • Primary Progressive Multiple Sclerosis
  • Ocrelizumab
  • Buffalo, New York
    Buffalo Neuroimaging Analysis Center
Jul 26, 2023

Ocrelizumab and Ofatumumab Administration in Relapsing Multiple

Completed
  • Relapsing Forms of Multiple Sclerosis
  • Lutherville, Maryland
  • +1 more
Oct 19, 2022

Symptom Burden in Patients Treated With Ocrelizumab for Multiple

Active, not recruiting
  • Multiple Sclerosis
  • Ocrelizumab
  • Wellesley, Massachusetts
  • +1 more
Oct 14, 2022

Relapsing-remitting Multiple Sclerosis Trial (CT-P53, US-Ocrevus, EU-Ocrevus)

Not yet recruiting
  • Relapsing-remitting Multiple Sclerosis
  • CT-P53
  • +2 more
  • (no location specified)
Jun 7, 2023

Multiple Sclerosis, Relapsing-Remitting Trial in Amsterdam (Ocrelizumab)

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Ocrelizumab
  • Amsterdam, Noord-Holland, Netherlands
    Amsterdam UMC, location VU
Apr 21, 2022

Multiple Sclerosis Trial in United States (Ocrelizumab, Placebo for Ocrelizumab)

Recruiting
  • Multiple Sclerosis
  • Ocrelizumab
  • Placebo for Ocrelizumab
  • New Haven, Connecticut
  • +9 more
Jan 17, 2023

RMS Patients on Ofatumumab or Ocrelizumab inReal-World Setting

Recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • Ocrelizumab
  • Dubai, United Arab Emirates
    Novartis Investigative Site
Aug 8, 2022

Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS Trial in Amsterdam

Recruiting
  • Multiple Sclerosis
  • +5 more
  • Amsterdam, Netherlands
    Amsterdam UMC, location VUmc
Apr 17, 2023

Multiple Sclerosis Trial in Moskva, Saint-Petersburg (Ocrelizumab)

Recruiting
  • Multiple Sclerosis
  • Ocrelizumab
  • Moskva, Moskovskaja Oblast, Russian Federation
  • +1 more
Aug 2, 2022

Multiple Sclerosis, Relapsing-Remitting, Fatigue Trial (TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY], Placebo)

Withdrawn
  • Multiple Sclerosis, Relapsing-Remitting
  • Fatigue
  • TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]
  • Placebo
  • Boston, Massachusetts
    Massachusetts General Hospital
Nov 14, 2022

Ocrelizumab in Breastmilk

Active, not recruiting
  • Multiple Sclerosis
  • Clinically Isolated Syndrome
  • Ocrelizumab
  • San Francisco, California
    University of California, San Francisco
Mar 21, 2022

Multiple Sclerosis, Clinically Isolated Syndrome Trial in Worldwide (Ocrelizumab)

Recruiting
  • Multiple Sclerosis
  • Clinically Isolated Syndrome
  • Ocrelizumab
  • San Francisco, California
  • +5 more
Aug 2, 2022

Physiological and Cognitive Changes in Multiple Sclerosis

Completed
  • Multiple Sclerosis
  • Ocrelizumab
  • Buffalo, New York
    Jacobs Institute
Mar 9, 2022

Mechanistic Study of Ocrevus

Recruiting
  • Multiple Sclerosis
  • Ocrelizumab
  • Ann Arbor, Michigan
    University of Michigan
Jul 27, 2022

WOE of Anti-CD20 Therapies

Not yet recruiting
  • Multiple Sclerosis
  • (no location specified)
Oct 31, 2023

Multiple Sclerosis Trial in France (Ocrelizumab)

Recruiting
  • Multiple Sclerosis
  • Ocrelizumab
  • Amiens, France
  • +14 more
Jul 12, 2022

Relapsing Multiple Sclerosis, Clinically Isolated Syndrome Trial in San Francisco (Ocrelizumab)

Recruiting
  • Relapsing Multiple Sclerosis
  • Clinically Isolated Syndrome
  • Ocrelizumab
  • San Francisco, California
    University of California San Francisco
Apr 28, 2022

Multiple Sclerosis, Clinically Isolated Syndrome Trial in Worldwide (Ocrelizumab)

Recruiting
  • Multiple Sclerosis
  • Clinically Isolated Syndrome
  • Ocrelizumab
  • San Francisco, California
  • +9 more
Aug 2, 2022

Relapsing-Remitting Multiple Sclerosis Trial in Hamburg, Mannheim (Autologous Hematopoietic Stem Cell Transplantation,

Terminated
  • Relapsing-Remitting Multiple Sclerosis
  • Autologous Hematopoietic Stem Cell Transplantation
  • +2 more
  • Hamburg, Germany
  • +1 more
Mar 1, 2022

Radiologically Isolated Syndrome, Multiple Sclerosis Trial in United States (Ocrelizumab, Placebo)

Recruiting
  • Radiologically Isolated Syndrome
  • Multiple Sclerosis
  • Ocrelizumab
  • Placebo
  • Los Angeles, California
  • +15 more
Jan 30, 2023

The 'Wearing Off' Effect of DMT

Recruiting
  • Multiple Sclerosis
  • ocrelizumab
  • +2 more
  • Basel, Switzerland
    Novartis Investigative Site
Jan 24, 2023

Ocrelizumab Access by Socio-Economic Status

Not yet recruiting
  • Multiple Sclerosis
  • Ocrelizumab
  • Boston, Massachusetts
    Brigham and Women's Hospital
Nov 22, 2021